Axovant Tumbles On Failed Drug, But Was Never Part Of The Game Plan [Seeking Alpha]
Axon Enterprise, Inc. (AXON)
Last axon enterprise, inc. earnings: 2/7 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.axovant.com/investors/sec-filings
Company Research
Source: Seeking Alpha
Summary Axovant Sciences announced that the phase 2 study using nelotanserin to treat patients with REM sleep behavior disorder has failed to meet on the primary endpoint. Based on the phase 2 failure with nelotanserin, Axovant has chosen to completely stop the entire development pathway for this program. The main focus in Axovant as of 2018 has been the newly funded licensed gene therapy products, some of which include AXO-Lenti-PD and AXO-AAV-OPMD. Results from the phase 2 study using AXO-Lenti-PD to treat patients with Parkinson's disease is expected to be read out by March of 2019. Another study using another kind of gene therapy, known as AXO-AAV-OPMD, is expected to be initiated by the second half of 2019. Recently, Axovant Sciences ( AXON ) announced that it had failed a phase 2 trial using a licensed drug known as nelotanserin to treat patients in a phase 2 study with REM sleep behavior disorder. The primary endpoint of this study was not met, and the bio
Show less
Read more
Impact Snapshot
Event Time:
AXON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXON alerts
High impacting Axon Enterprise, Inc. news events
Weekly update
A roundup of the hottest topics
AXON
News
- Axon Enterprise, Inc. (NASDAQ: AXON) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Axon Enterprise, Inc. (NASDAQ: AXON) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $400.00 price target on the stock.MarketBeat
- Axon reimagines report writing with Draft One, a first-of-its-kind AI-powered force multiplier for public safety [Yahoo! Finance]Yahoo! Finance
- Axon reimagines report writing with Draft One, a first-of-its-kind AI-powered force multiplier for public safetyPR Newswire
- Axon Enterprise (AXON) Stock Slides as Market Rises: Facts to Know Before You Trade [Yahoo! Finance]Yahoo! Finance
AXON
Earnings
- 2/27/24 - Beat
AXON
Sec Filings
- 4/19/24 - Form POSASR
- 4/15/24 - Form DEFA14A
- 4/15/24 - Form DEFA14A
- AXON's page on the SEC website